Antiepileptic drug effects on subjective and objective cognition

Quon, Robert J.; Mazanec, Morgan T; Schmidt, Samantha; Andrew, Angeline S.; Roth, Robert M.; MacKenzie, Todd A.; Sajatovic, Martha; Spruill, Tanya M.; Jobst, Barbara C.

doi:10.1016/j.yebeh.2020.106906

Cited by 37 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…People can experience cognitive impairment not only due to seizures but also due to antiepileptics. The antiepileptic drug type, in itself, does not appear to be associated with subjective cognition 13 . A cross‐sectional study by Foster et al .…”

Section: Discussionmentioning

confidence: 97%

“…It is important to monitor cognitive side‐effects by detailed and repeated questioning of patients or their caregivers during antiepileptic medication reviews 12 . Ineffective antiepileptics should be replaced, rather than introducing additional antiepileptics to a treatment regimen 13 . The best possible seizure control or seizure reduction is vital.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A dementia‐like picture: could it be the medication?

Bangash

Bharmal

2021

Prog Neurol Psychiatry

View full text Add to dashboard Cite

Recognition of drug‐induced cognitive decline is helpful in that omission of the offending agent can often reverse the cognitive dysfunction. Older people are more likely to develop drug‐related cognitive side‐effects in contrast to younger patients due to age‐related changes in brain neurochemistry. Here, Dr Bangash and Dr Bharmal discuss such a case involving the epilepsy medication topiramate.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

A dementia‐like picture: could it be the medication?

Bangash

Bharmal

2021

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

“…Polytherapy is also a well-recognized factor that contributes to increase ASM-related CAEs probably through a potentiation in adverse effects of two or more drugs or for contextual presence of comorbidities and drug-resistant epilepsy in patients where polytherapy is necessary [ 111 ]. Furthermore, the number of ASMs in a treatment regimen seems more strongly associated with changes in cognition than the type of ASM [ 136 ].…”

Section: Antiseizure Medications and Alzheimer’s Diseasementioning

confidence: 99%

Temporal Lobe Epilepsy and Alzheimer’s Disease: From Preclinical to Clinical Evidence of a Strong Association

Tombini

Assenza

Ricci

et al. 2021

ADR

View full text Add to dashboard Cite

Increasing evidence coming from both experimental and humans’ studies strongly suggest the existence of a link between epilepsy, in particular temporal lobe epilepsy (TLE), and Alzheimer’s disease (AD). Patients with mild cognitive impairment and AD are more prone to have seizures, and seizures seem to facilitate amyloid-β and tau deposits, thus promoting neurodegenerative processes. Consistent with this view, long-lasting drug-resistant TLE and AD have been shown to share several pathological and neuroimaging features. Even if studies addressing prevalence of interictal and subclinical epileptiform activity in these patients are not yet conclusive, their findings raise the possibility that epileptiform activity might negatively impact memory and hasten cognitive decline, either directly or by association with unrecognized silent seizures. In addition, data about detrimental effect of network hyperexcitability in temporal regions in the premorbid and early stages ofADopen up newtherapeutic opportunities for antiseizure medications and/or antiepileptic strategies that might complement or enhance existing therapies, and potentially modify disease progression. Here we provide a review of evidence linking epileptiform activity, network hyperexcitability, and AD, and their role promoting and accelerating neurodegenerative process. Finally, the effects of antiseizure medications on cognition and their optimal administration in patients with AD are summarized.

show abstract

“…In more recent years, tolerability research has paid increasing attention to the AEs of ASMs on cognitive function, especially in children and adolescents, whose central nervous system is still developing ( 14 , 15 ). Regarding PER, the data currently available seem encouraging.…”

Section: Introductionmentioning

confidence: 99%

Perampanel and Visuospatial Skills in Children With Epilepsy

et al. 2021

View full text Add to dashboard Cite

Introduction: Perampanel (PER) is a non-competitive AMPA glutamate receptor antagonist approved for focal and generalized seizures as add-on therapy. PER does not seem to negatively affect the cognitive profile in children and adolescents, but its influence on visuospatial abilities is still to be assessed. The aim of our study was to assess visuospatial skills through a standardized neuropsychological evaluation in adolescents taking PER for 12 months.Methods: Our sample included 46 adolescents aged 12–18 years with focal and generalized drug-resistant epilepsy already in therapy with one or two antiseizure medications. Changes in visuospatial perception and memory were assessed by the Rey–Osterrieth Complex Figure Test at baseline (before taking PER) and after 12 months of pharmacological treatment. Executive functions and non-verbal intelligence were also assessed at baseline.Results: After 12 months of PER therapy, the mean scores on the Rey–Osterrieth Complex Figure Test remained almost unchanged for both visuospatial perception and visuospatial memory skills. At baseline, visuospatial memory was related to executive function, and visuospatial perception was related to executive function and non-verbal intelligence.Conclusions: Adjunctive treatment with PER did not negatively affect visuospatial skills. No adverse event effects have been reported after 12 months of follow-up, and this suggests a good tolerability in the middle-to-long term.

show abstract

Antiepileptic drug effects on subjective and objective cognition

Cited by 37 publications

References 37 publications

A dementia‐like picture: could it be the medication?

A dementia‐like picture: could it be the medication?

Temporal Lobe Epilepsy and Alzheimer’s Disease: From Preclinical to Clinical Evidence of a Strong Association

Perampanel and Visuospatial Skills in Children With Epilepsy

Contact Info

Product

Resources

About